- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
A flurry of capital raises highlights the changing outlook for a number of industries.
Changing monthly data portend a shift for staffers and shippers, and the rig-cutting cycle nears an end.
But if the rally cools, some of these ideas may move still lower.
The newly appreciated stock will have to contend with the industry's inventory issues.
The e-reader has only a fringe following, but it could slow the bookseller's rebound.
The company leaves its Revlimid target set too high, setting it up for disappointment.
Although they're getting harder to find, there are still cheap stocks heading to the upside.
The coming economic calendar will give clues to a possible snapback in the economy.
Be careful, though - the company's mergers and partnerships come with risk.
The focus was on new drugs under development and bringing them to market.